“…In clinical practice, RT is used in different phases of treatment for 60–70% of patients with malignant tumors . Unfortunately, the therapeutic use of RT in cancer treatment is severely constrained by radioresistance brought on by intratumoral hypoxia and the toxicity of high-dose radiation for surrounding healthy tissues. − It is well known that hypoxia is one of the defining characteristics of most solid tumors and an important cause of cancer progression and poor prognosis. − During RT, the hypoxic environment reduces the production of ROS and cytotoxic substances. , In addition, reducing substances, including sulfhydryl-containing molecules within the tumor, can significantly reduce the ionizing damage to the genomic DNA of cancer cells caused by ionizing radiation. − To address these issues, a variety of radiosensitizers that attempt to increase the radiation sensitivity of cancer cells have been developed and used in clinical settings, including sodium glycidazole and nimozole. − However, due to the low bioavailability in the body, large doses of sensitizers are required to achieve satisfactory radiosensitization effects, leading to serious negative impacts on healthy tissues, organs, and the central nervous system. High-atomic-number (high-Z) metals have received a lot of interest in the field of radiosensitization because they can greatly enhance the attenuation of X-rays and facilitate the deposition of radiation energy within the tumor. − To date, many nanoplatforms containing high-Z elements for radiosensitization have been successfully developed. − However, most of the current nanomedicines are unable to penetrate tumors and cannot reach cancer cells located far from the tumor-associated blood vessels, especially in the hypoxic area.…”